This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Dermatopolymyositis
M13_DERMATOPOLY
dermatomyositis: Dermatomyositis (DM) is a type of idiopathic inflammatory myopathy characterized by evocative skin lesions and symmetrical proximal muscle weakness.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
498 |
4. Check minimum number of eventsNone |
498 |
5. Include endpoints |
537 |
6. Filter based on genotype QC (FinnGen only) |
537 |
Control definitions (FinnGen only)
- Control exclude
- M13_SYSTCONNECT
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M30-M36
- Name in latin
- Dermato[poly]myositis
Similar endpoints
↥List of similar endpoints to
Dermatopolymyositis
based on the number of shared cases.
Similar with more cases:
- Systemic connective tissue disorders
- Autoimmune diseases related-to ILD
- Autoimmune diseases
- Used for control exclusion in common control thyroid runs
- Diseases of the musculoskeletal system and connective tissue
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 537 | 332 | 205 |
| Unadjusted period prevalence (%) | 0.10 | 0.11 | 0.09 |
| Median age at first event (years) | 54.47 | 53.17 | 56.59 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 496
- Matched controls
- 4960
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M33.2
ICD-10 Finland
Polymyositis
+∞
275.5
238
*
M33.9
ICD-10 Finland
Dermatopolymyositis, unspecified
+∞
190.1
170
*
M33.1
ICD-10 Finland
Other dermatomyositis
+∞
171.0
154
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
21.2
166.1
275
275
L04AX01
ATC
azathioprine; systemic
26.6
106.3
151
80
M60.9
ICD-10 Finland
Myositis, unspecified
189.5
103.7
105
7
L04AX03
ATC
methotrexate; systemic (immunosuppressants)
12.6
98.1
195
242
H02AB06
ATC
prednisolone; systemic
8.3
94.1
396
1604
P01BA02
ATC
hydroxychloroquine; oral
13.0
85.2
163
180
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
6.6
82.3
316
1043
M35.9
ICD-10 Finland
Systemic involvement of connective tissue, unspecified
782.9
70.9
68
*
G72.9
ICD-10 Finland
Myopathy, unspecified
81.2
68.5
76
11
NK6QA
NOMESCO Finland
Measurement of bone density from tow or more locations with X-ray
13.4
66.9
123
119
M05BA04
ATC
alendronic acid; oral
9.8
60.5
132
176
NXL00
NOMESCO Finland
Biopsy of muscle
143.8
60.4
63
5
NJ3CG
NOMESCO Finland
Extensive MRI examination of extremities with median high magnet
218.2
57.3
58
*
NJ3BG
NOMESCO Finland
MRI examination of extremities with high intensity magnet
+∞
54.1
51
*
M35.0
ICD-10 Finland
Sicca syndrome [Sjögren]
168.4
44.6
46
*
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
8.9
43.1
97
131
L04AA06
ATC
mycophenolic acid; systemic
27.7
43.1
59
24
M60.8
ICD-10 Finland
Other myositis
101.1
42.6
46
5
M33.0
ICD-10 Finland
Juvenile dermatomyositis
+∞
40.1
38
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
6.3
39.1
114
224
H02AB07
ATC
prednisone; oral
4.7
36.9
147
411
J99.1*M33.2
ICD-10 Finland
Respiratory disorders in polymyositis
+∞
35.9
34
*
L01BA01
ATC
methotrexate; systemic (folic acid analog.)
8.7
31.8
71
93
M35.1
ICD-10 Finland
Other overlap syndromes
+∞
31.6
30
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.1
31.5
282
1477
L04AD01
ATC
ciclosporin; systemic
17.0
30.1
48
31
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
7.7
28.9
70
104
M05BA07
ATC
risedronic acid; oral
11.2
25.1
48
47
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
5.7
24.8
75
150
L04AA01
ATC
[U] ciclosporin; systemic
15.7
23.3
38
26
M32.9
ICD-10 Finland
Systemic lupus erythematosus, unspecified
+∞
23.1
22
*
J99.1
ICD-10 Finland
Respiratory disorders in other diffuse connective tissue disorders
+∞
22.0
21
*
L88
ICPC
Rheumatoid/seropositive arthritis
7.7
21.5
51
73
7104A
ICD-9 Finland
Diffuse diseases of connective tissue, Polymyositis
+∞
21.0
20
*
NGA20
NOMESCO Finland
Exploration of soft tissue knee or lower leg, open
80.3
20.8
23
*
71610
ICD-8 Finland
Polymyositis and dermatomyositis, Polymyositis
+∞
19.9
19
*
J99.1*M33.9
ICD-10 Finland
Respiratory disorders in dermatopolymyositis
+∞
19.9
19
*
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.6
19.9
188
937
M35.3
ICD-10 Finland
Polymyalgia rheumatica
14.9
18.8
31
22
R50.9
ICD-10 Finland
Fever, unspecified
3.4
18.8
102
353
J84.9
ICD-10 Finland
Interstitial pulmonary disease, unspecified
10.4
17.9
35
36
L99
ICPC
Musculoskeletal disease other
12.1
17.8
32
28
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.6
17.0
147
684
J84.1
ICD-10 Finland
Other interstitial pulmonary diseases with fibrosis
11.3
16.7
31
29
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
7.7
16.3
38
53
R13
ICD-10 Finland
Dysphagia
4.6
16.1
57
135
C03CA01
ATC
furosemide; systemic
2.4
15.9
171
890
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.1
15.9
98
369
ZX120
NOMESCO Finland
Intravenous
3.5
15.7
78
251
XG410
NOMESCO Finland
Flow-volume spirometry
6.2
15.2
41
71
L30.9
ICD-10 Finland
Dermatitis, unspecified
2.8
15.0
112
475
A02BC02
ATC
pantoprazole; systemic
2.2
14.8
338
2454
71600
ICD-8 Finland
Polymyositis and dermatomyositis, Dermatomyositis
+∞
14.6
14
*
G72.8
ICD-10 Finland
Other specified myopathies
11.9
14.4
26
23
J84.8
ICD-10 Finland
Other specified interstitial pulmonary diseases
15.0
14.2
23
16
XX9XE
NOMESCO Finland
Other ultrasound examination
18.2
13.9
21
12
E0000UV
ATC
NA
2.1
13.9
207
1240
R4110
NOMESCO Finland
Physiotherapy
2.3
13.8
157
830
UGC12
NOMESCO Finland
Flexible bronchoscopy
3.7
13.6
61
180
7103B
ICD-9 Finland
Diffuse diseases of connective tissue, Dermatomyositis[DERMATOMYOSITIS ADULTORUM]
+∞
13.6
13
*
M33
ICD-10 Finland
Dermatopolymyositis
+∞
13.6
13
*
TPH04
NOMESCO Finland
Cathetrisation of vein
2.4
13.5
129
623
TGC00
NOMESCO Finland
Bronchial lavation
6.9
13.3
33
51
L28
ICPC
Limited function/disability (L)
2.7
13.1
99
422
XPX04
NOMESCO Finland
Angioscopy
51.4
12.9
15
*
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
2.4
12.7
120
574
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.1
12.7
73
261
R06.0
ICD-10 Finland
Dyspnoea
2.3
12.5
141
737
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
2.5
12.5
105
473
L19
ICPC
Muscle symptom/complaint NOS
7.1
12.1
29
43
JN4BD
NOMESCO Finland
Extensive body CT
2.9
11.9
79
308
NJ3DG
NOMESCO Finland
Very extensive MRI examination of extremities with high intensity magnet
66.5
11.7
13
*
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
4.0
11.5
46
123
N03AX16
ATC
pregabalin; oral
2.2
11.5
131
684
H05AA02
ATC
teriparatide; parenteral
44.3
11.0
13
*
R4120
NOMESCO Finland
Occupational therapy
3.6
10.9
50
151
H26.3
ICD-10 Finland
Drug-induced cataract
18.3
10.8
16
9
D07AC01
ATC
betamethasone; topical
2.0
10.7
178
1086
G71.9
ICD-10 Finland
Primary disorder of muscle, unspecified
61.3
10.7
12
*
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
3.1
10.6
59
204
D07AB08
ATC
desonide; topical
2.8
10.5
71
279
E000001
ATC
NA
2.3
10.5
107
530
318
Kela drug reimbursment
Teriparatide
33.3
10.4
13
*
XA402
NOMESCO Finland
ENMG
5.3
10.2
30
59
Z01.8
ICD-10 Finland
Other specified special examinations
2.2
9.9
119
633
A07AA02
ATC
nystatin; oral
3.4
9.9
48
152
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
2.8
9.9
64
246
C08CA05
ATC
nifedipine; systemic
3.3
9.8
49
159
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
3.7
9.7
42
121
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
3.5
9.6
44
133
NG4AA
NOMESCO Finland
Lower leg X-ray examination
5.3
9.2
27
53
XG470
NOMESCO Finland
Measurement of diffusion capastity of the lungs
5.0
9.0
28
59
Z50.1
ICD-10 Finland
Other physical therapy
3.8
8.9
37
103
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
2.9
8.9
55
205
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
1.8
8.9
202
1358
1XC02
NOMESCO Finland
NA
11.8
8.6
15
13
L93.0
ICD-10 Finland
Discoid lupus erythematosus
28.0
8.5
11
*
M13.9
ICD-10 Finland
Arthritis, unspecified
3.0
8.5
48
169
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
4.3
8.4
30
73
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
3.9
8.4
33
88
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
2.9
8.4
52
194
QC6S1
NOMESCO Finland
Photography of skin or subcutaneous tissue in hand
+∞
8.4
8
*
7103A
ICD-9 Finland
Diffuse diseases of connective tissue, Dermatomyositis[DERMATOMYOSITIS JUVENILIS]
+∞
8.4
8
*
H02AB04
ATC
methylprednisolone; systemic
2.3
8.3
80
381
XQ848
NOMESCO Finland
Dermatological photography
5.6
8.2
23
43
NF1AE
NOMESCO Finland
Hip joint ultrasound examination
5.6
8.2
23
43
M05BX04
ATC
denosumab; parenteral
3.6
8.2
35
101
M62.9
ICD-10 Finland
Disorder of muscle, unspecified
17.5
8.1
12
7
M05BA01
ATC
etidronic acid; systemic
33.9
8.1
10
*
M05BB03
ATC
alendronic acid and colecalciferol; oral
6.5
8.1
20
32
M81.4
ICD-10 Finland
Drug-induced osteoporosis
22.4
8.0
11
5
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
1.9
7.9
149
933
M79.0
ICD-10 Finland
Rheumatism, unspecified
4.2
7.9
29
73
J01DB01
ATC
cefalexin; oral
1.9
7.9
388
3269
Z46.8
ICD-10 Finland
Fitting and adjustment of other specified devices
6.5
7.8
19
30
A02BC01
ATC
omeprazole; systemic
1.9
7.7
144
895
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
2.6
7.6
56
234
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
1.8
7.6
146
916
5BA08
NOMESCO Finland
NA
13.6
7.4
12
9
J05AB01
ATC
aciclovir; systemic
1.9
7.4
114
664
EBA10
NOMESCO Finland
Surgical removal of tooth
2.4
7.4
62
276
WZA10
NOMESCO Finland
Long statement of health and health related matters
8.5
7.4
15
18
QBA99
NOMESCO Finland
Other local destruction of skin of trunk
11.1
7.3
13
12
M60.0
ICD-10 Finland
Infective myositis
+∞
7.3
7
*
M31.1
ICD-10 Finland
Thrombotic microangiopathy
+∞
7.3
7
*
G73.7*M35.0
ICD-10 Finland
Myopathy in sicca syndrome [Sjögren]
+∞
7.3
7
*
D07AC13
ATC
mometasone; topical
1.8
7.3
142
895
C07AB07
ATC
bisoprolol; oral
1.7
7.2
222
1610
RF420
NOMESCO Finland
NA
6.7
7.2
17
26
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
2.3
7.1
66
310
A01AB09
ATC
miconazole; local oral
2.6
7.1
52
217
M05BA06
ATC
ibandronic acid; systemic
7.1
7.0
16
23
SPAT1231
SPAT
Assessment of adjustments needed in living environment
6.0
7.0
18
31
A28
ICPC
Limited function/disability NOS
2.1
6.9
76
386
XG466
NOMESCO Finland
Sleep oxymetry
4.3
6.9
24
58
RF410
NOMESCO Finland
NA
8.4
6.9
14
17
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
2.7
6.8
44
170
N28
ICPC
Limited function/disability (N)
6.2
6.8
17
28
UJF30
NOMESCO Finland
Ileoscopy through colon
2.4
6.8
54
236
XX6XT
NOMESCO Finland
Other intravascular therapy with radiological guidance
40.6
6.8
8
*
J01FF01
ATC
clindamycin; systemic
1.8
6.8
132
830
M79.1
ICD-10 Finland
Myalgia
2.2
6.7
70
348
L29
ICPC
Musculoskeletal sympt/complt other
2.6
6.6
46
186
SPAT1229
SPAT
Assessment of need for aid
2.7
6.6
45
179
S18
ICPC
Laceration/cut
1.7
6.5
199
1426
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
2.3
6.5
61
286
G71.08
ICD-10 Finland
Other muscular dystrophy
70.7
6.4
7
*
GCA98
NOMESCO Finland
Other bronchoscopic procedure on bronchus
14.5
6.4
10
7
F43.29
ICD-10 Finland
Adaptation disorder UNS
6.7
6.4
15
23
H05BA01
ATC
calcitonin (salmon synthetic); nasal, parenteral
3.8
6.4
25
68
RF120
NOMESCO Finland
NA
8.3
6.4
13
16
A02BC03
ATC
lansoprazole; oral
1.7
6.4
143
937
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
2.3
6.3
60
283
SBA10
NOMESCO Finland
Measurement of excretion of saliva
11.2
6.3
11
10
M80.4
ICD-10 Finland
Drug-induced osteoporosis with pathological fracture
18.3
6.3
9
5
M32.0
ICD-10 Finland
Drug-induced systemic lupus erythematosus
+∞
6.3
6
*
M34.1
ICD-10 Finland
CR(E)ST syndrome
+∞
6.3
6
*
H02AB09
ATC
hydrocortisone; systemic
4.6
6.2
20
45
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
1.6
6.1
187
1337
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
2.5
6.1
46
194
NA3AD
NOMESCO Finland
Lumbar spine and sacrum CT examination
4.5
6.1
20
46
TND11
NOMESCO Finland
Injection of diagnostic or therapeutic substance in joint, wrist or hand
6.8
6.1
14
21
PJ2AE
NOMESCO Finland
Lymphnode ultrasound examination
10.2
6.1
11
11
SPAT1148
SPAT
Treatment of chronic ulcer or burn
2.2
6.0
63
312
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
113
16
89.18
213.05
1.4
1.0
—
—
—
0
0
158
122
17.93
173.31
6.0
2.2
550.0
311.9
ug/l
0.50
152
115
390
1213
9.09
135.17
12.1
2.0
237.4
268.7
u/l
0.22
385
1147
108
78
17.08
121.17
1.7
1.1
50.0
—
u/ml
—
10
0
120
131
11.51
103.63
1.5
1.1
4.1
3.1
u/ml
—
8
6
112
117
11.83
99.58
2.2
1.3
—
—
—
0
0
98
100
11.76
88.18
1.5
1.1
12.4
3.8
u/ml
—
25
8
97
98
11.86
87.86
1.5
1.1
1.8
3.2
u/ml
—
13
6
63
8
89.14
57.37
1.3
1.0
—
—
—
0
0
71
83
9.71
57.23
1.4
1.1
54.5
7.0
u/ml
—
23
5
45
27
18.10
54.51
1.4
1.1
—
—
—
0
0
45
27
18.10
54.51
1.4
1.1
—
—
—
0
0
45
28
17.45
53.54
1.4
1.1
—
—
—
0
0
45
28
17.45
53.54
1.4
1.1
—
—
—
0
0
45
28
17.45
53.54
1.4
1.1
—
—
—
0
0
80
122
7.53
51.62
1.6
1.5
300.1
0.2
iu/ml
0.47
11
20
384
2030
4.13
50.81
17.2
5.8
26.2
28.0
%
2.65
377
1894
381
2005
4.10
50.72
16.7
5.6
59.2
57.1
%
2.73
374
1878
418
2436
4.23
45.75
19.4
9.2
4.2
4.1
e9/l
0.58
401
2148
122
376
3.90
34.67
1.8
2.0
358.0
379.7
nmol/l
0.24
115
347
326
1917
2.78
29.08
10.3
5.7
1.2
1.2
mmol/l
0.06
310
1731
29
25
12.21
28.48
1.5
1.2
2.2
—
u/ml
—
5
0
340
2089
2.71
27.02
11.9
6.5
1.2
1.2
mmol/l
0.44
296
1762
29
28
10.89
26.44
1.6
1.2
103.5
—
u/ml
—
8
0
58
124
5.12
26.12
3.0
2.1
3.1
3.1
g/l
0.04
51
100
27
24
11.79
25.97
2.3
2.1
18.6
12.5
%
0.94
14
15
57
122
5.11
25.62
3.0
2.1
10.3
10.6
g/l
0.12
51
109
26
23
11.83
25.07
2.3
2.1
—
—
—
0
0
30
33
9.57
24.95
1.6
1.1
—
—
—
0
0
59
134
4.82
24.73
3.0
2.0
3.5
3.7
g/l
0.80
50
97
59
134
4.82
24.73
3.0
2.0
7.2
7.3
g/l
0.19
52
101
59
134
4.82
24.73
3.0
2.0
—
—
—
0
0
294
1738
2.53
24.44
3.2
2.3
76.3
77.4
nmol/l
0.26
277
1542
442
3213
3.12
23.61
12.8
3.7
14.9
11.8
mm/h
4.47
429
2945
49
102
5.19
22.69
3.3
2.2
0.0
0.1
g/l
0.50
49
96
47
96
5.27
22.23
3.4
2.3
0.0
0.0
g/l
0.00
47
90
47
96
5.27
22.23
3.4
2.3
0.0
0.0
g/l
0.00
47
90
56
136
4.48
21.56
3.2
2.9
—
—
—
0
0
42
81
5.54
21.14
10.0
6.8
519.6
229.8
iu/ml
—
9
12
143
654
2.62
19.77
6.5
3.5
0.8
0.8
mmol/l
0.71
135
617
25
32
8.15
18.43
2.1
1.8
364.2
485.6
e6/l
0.61
18
23
314
2071
2.24
18.32
5.3
3.5
0.0
0.0
estimate
0.00
64
389
281
1784
2.21
17.89
7.2
4.6
34.1
35.7
g/l
4.11
271
1666
141
676
2.47
17.41
2.3
1.8
—
—
—
0
0
212
1212
2.24
17.41
4.6
3.0
1086.1
1252.6
ng/l
0.36
193
1026
434
3327
2.59
17.17
16.4
7.1
73.9
78.4
u/l
1.08
429
3098
314
2111
2.17
16.95
5.4
3.6
0.0
0.0
estimate
0.50
68
376
84
314
2.99
16.88
4.3
3.2
186.0
177.7
ng/l
0.08
75
291
23
30
7.96
16.67
1.3
1.1
74.0
95.0
titre
—
10
6
310
2089
2.14
16.44
7.1
4.9
0.0
0.0
estimate
0.00
67
390
23
31
7.71
16.22
2.2
1.8
0.2
0.2
e9/l
0.47
18
23
118
537
2.53
16.18
2.9
2.4
22.9
23.0
%
0.02
103
468
43
115
3.98
14.53
1.8
1.6
—
—
—
0
0
25
42
6.19
14.44
2.4
1.5
—
—
—
0
0
43
118
3.87
14.02
1.3
1.2
—
—
—
0
0
34
78
4.59
14.00
1.5
1.4
—
—
—
0
0
34
79
4.53
13.78
1.2
1.5
—
—
—
0
0
197
1178
2.06
13.72
4.3
3.0
0.3
0.5
e6/l
1.43
159
884
32
72
4.66
13.48
1.4
1.4
96.3
107.7
u/ml
—
6
12
42
119
3.74
13.09
1.8
1.6
—
—
—
0
0
132
691
2.21
12.89
1.4
1.2
61.6
36.6
iu/ml
0.69
42
221
32
75
4.47
12.83
1.2
1.5
289.9
265.6
u/ml
0.13
22
40
74
300
2.70
12.67
2.4
2.5
11.3
18.3
au/ml
—
5
14
166
956
2.07
12.63
1.3
1.2
0.8
1.7
u/ml
0.95
35
254
218
1388
1.96
12.45
6.2
3.2
48.4
31.4
u/l
3.11
208
1323
107
523
2.31
12.28
8.5
5.6
1.1
1.0
mmol/l
0.05
102
486
39
110
3.74
12.23
5.7
4.6
34.2
31.2
mg/l
0.12
32
88
31
75
4.33
11.95
5.0
3.3
61.2
59.0
%
0.36
31
75
30
71
4.42
11.88
4.6
3.0
4.5
4.7
e9/l
0.14
30
71
100
482
2.32
11.83
2.2
1.8
—
—
—
0
0
132
719
2.11
11.52
3.4
2.8
0.7
1.1
e6/l
2.04
88
403
38
110
3.64
11.48
5.9
4.6
45.1
117.1
mg/l
0.63
32
87
168
1003
1.98
11.38
2.7
2.0
3.3
3.2
mg/l
0.26
151
852
32
83
4.04
11.27
1.8
1.5
—
—
—
0
0
19
31
6.32
11.27
2.1
2.1
924.7
568.9
e6/l
—
7
14
33
89
3.89
11.02
1.8
1.6
—
—
—
0
0
307
2256
1.84
10.72
8.6
6.1
10.0
11.2
umol/l
2.15
295
2127
96
479
2.22
10.39
2.2
1.7
—
—
—
0
0
25
58
4.47
10.15
1.0
1.2
3.0
6.0
u/ml
0.31
11
17
68
295
2.49
10.10
2.1
1.6
—
—
—
0
0
22
46
4.94
10.09
1.0
1.1
—
—
—
0
0
11
11
10.19
9.57
1.9
1.3
8.4
8.2
ug/l
0.05
11
11
26
69
3.91
8.89
2.0
1.5
—
—
—
0
0
24
60
4.14
8.88
1.4
1.5
—
—
—
0
0
135
810
1.89
8.70
6.0
3.8
235.1
234.0
ng/l
0.00
115
626
90
470
2.10
8.60
13.4
6.8
10.5
12.3
kpa
3.40
80
454
90
470
2.10
8.60
13.4
6.8
5.2
5.1
kpa
0.30
80
453
127
751
1.91
8.54
1.8
1.7
1121.8
1178.5
nmol/l
0.31
103
568
16
29
5.66
8.54
1.1
1.3
—
—
—
0
0
12
6
20.41
8.50
1.8
2.2
—
—
—
0
0
248
1791
1.71
8.48
3.6
2.7
189.2
119.3
ug/l
2.23
236
1646
13
19
6.99
8.48
2.0
1.3
—
—
—
0
0
21
49
4.42
8.47
1.7
1.9
—
—
—
0
0
12
16
7.65
8.44
1.0
1.1
1.1
1.1
ratio
—
6
5
208
1436
1.73
8.34
3.5
3.3
2.3
2.4
mmol/l
1.96
191
1256
22
54
4.21
8.33
1.7
1.8
—
—
—
0
0
353
2820
1.73
8.21
6.3
4.4
15.4
2715.0
e6/l
—
5
46
24
64
3.88
8.15
2.0
1.5
—
—
—
0
0
70
338
2.23
8.14
2.9
2.3
18.4
6.6
ug/l
2.44
61
295
21
51
4.24
8.06
1.2
1.4
—
—
—
0
0
88
469
2.05
7.94
13.7
6.9
1.5
1.2
mmol/l
0.22
67
376
25
70
3.70
7.94
1.4
1.5
—
—
—
0
0
164
1078
1.75
7.72
4.0
2.6
2701.3
7702.7
umol/l
1.09
151
930
115
681
1.88
7.63
1.3
1.2
33.8
14.9
u/ml
0.52
33
258
189
1301
1.70
7.49
2.7
2.3
54.4
55.6
u/l
0.23
174
1197
13
23
5.77
7.09
1.0
1.2
—
—
—
0
0
112
673
1.84
7.06
3.8
2.9
3.3
2.3
e6/l
0.66
70
362
150
989
1.72
6.87
1.7
1.5
19.7
21.3
nmol/l
0.79
132
833
22
63
3.60
6.78
1.0
1.2
2.4
4.6
u/ml
—
8
30
311
2481
1.60
6.56
8.9
4.5
6.6
6.7
mmol/l
0.38
298
2313
47
210
2.36
6.55
18.1
8.7
24.7
24.6
mmol/l
0.06
42
199
85
479
1.92
6.51
3.4
3.0
6.5
8.0
umol/l
0.57
72
420
11
19
5.89
6.13
1.7
3.2
1187.1
998.7
u/ml
0.23
11
19
9
6
15.22
5.92
1.1
1.3
—
—
—
0
0
27
98
2.85
5.71
1.2
1.6
—
—
—
0
0
15
37
4.14
5.66
1.1
1.0
—
—
—
0
0
10
17
5.97
5.64
1.0
1.1
—
—
—
0
0
13
29
4.57
5.54
1.5
3.3
—
—
—
0
0
19
57
3.42
5.49
2.2
1.5
—
—
—
0
0
215
1623
1.54
5.45
5.2
3.5
95.2
37.1
ng/l
2.35
181
1113
159
1122
1.59
5.41
6.5
3.8
0.0
0.0
estimate
0.00
67
383
17
49
3.55
5.21
1.4
1.4
12.2
65.0
%
—
9
35
16
46
3.55
4.93
1.5
1.7
—
—
—
0
0
16
46
3.55
4.93
1.5
1.7
—
—
—
0
0
16
46
3.55
4.93
1.5
1.7
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
28
113
2.56
4.87
5.0
2.5
0.4
0.4
u/ml
0.01
19
55
24
91
2.71
4.72
2.5
1.4
—
—
—
0
0
31
134
2.39
4.68
1.4
1.1
—
—
—
0
0
135
947
1.57
4.63
2.2
1.8
1.2
1.1
mg/l
0.21
101
747
9
11
8.30
4.57
1.1
1.0
—
—
—
0
0
220
1720
1.47
4.49
2.2
2.0
95.1
94.9
pmol/l
0.02
121
871
22
82
2.75
4.47
1.5
1.5
—
—
—
0
0
207
1604
1.47
4.40
5.9
3.7
—
—
—
0
0
30
132
2.35
4.37
1.3
1.1
—
—
—
0
0
27
115
2.42
4.23
1.5
1.3
—
—
—
0
0
12
32
3.81
4.10
1.0
1.1
—
—
—
0
0
23
92
2.57
4.10
1.5
1.2
—
—
—
0
0
23
92
2.57
4.10
1.5
1.2
—
—
—
0
0
80
511
1.66
3.99
27.5
22.3
1.7
1.3
inr
—
8
70
44
238
1.92
3.83
2.0
1.7
—
—
—
0
0
9
16
5.70
3.67
3.3
1.7
61.6
53.1
ug/l
—
9
16
61
374
1.71
3.55
6.0
4.4
2.1
2.0
mmol/l
0.10
53
302
9
17
5.36
3.52
1.0
1.1
90.7
225.5
iu/ml
—
9
17
32
160
2.06
3.47
2.7
1.9
—
—
—
0
0
467
4325
1.61
3.45
31.5
13.1
19.4
23.2
mg/l
2.40
431
3385
112
803
1.50
3.40
2.4
2.8
2.5
2.5
mmol/l
1.01
94
715
8
14
5.78
3.35
1.3
1.6
—
—
—
0
0
62
392
1.66
3.23
18.3
7.5
120.7
121.2
g/l
0.07
57
381
118
868
1.46
3.14
1.6
1.8
63636809.2
6983681.2
pmol/l
0.42
110
716
64
412
1.63
3.11
2.3
2.3
361.3
34.0
u/l
0.49
55
350
11
34
3.28
3.07
1.4
1.4
—
—
—
0
0
25
120
2.14
3.03
1.6
1.3
—
—
—
0
0
43
250
1.78
3.03
1.6
1.4
—
—
—
0
0
39
222
1.82
2.94
1.4
1.3
—
—
—
0
0
16
64
2.55
2.89
1.1
1.1
—
—
—
0
0
22
104
2.16
2.78
1.7
1.6
4675.6
18923.4
e6/l
1.40
16
76
319
2809
1.33
2.71
4.1
3.1
54.1
46.3
u/l
0.92
306
2616
393
4244
0.72
2.70
4.9
4.4
1.4
1.5
mmol/l
4.07
370
3910
36
207
1.79
2.65
1.0
1.0
—
—
—
0
0
119
908
1.40
2.57
6.9
3.9
1.0
1.0
kg/l
0.25
19
131
5
7
7.20
2.55
3.8
1.4
—
—
—
0
0
397
4269
0.73
2.52
4.8
4.4
4.8
4.7
mmol/l
1.77
373
3945
9
26
3.50
2.49
1.0
1.0
—
—
—
0
0
42
259
1.67
2.44
11.7
7.0
24.9
24.6
mmol/l
0.17
37
245
24
125
1.96
2.39
1.3
1.3
300.9
297.5
ug/g
0.03
16
75
19
368
0.50
2.38
1.7
1.7
—
—
—
0
0
27
147
1.88
2.37
2.5
1.7
—
—
—
0
0
8
22
3.67
2.37
1.3
1.4
—
—
—
0
0
8
22
3.67
2.37
1.3
1.4
—
—
—
0
0
8
22
3.67
2.37
1.5
1.1
—
—
—
0
0
378
4079
0.75
2.30
4.5
4.0
1.5
1.3
mmol/l
3.80
356
3740
23
121
1.94
2.24
1.3
1.5
—
—
—
0
0
408
4351
0.74
2.24
5.1
5.0
2.9
2.8
mmol/l
2.25
386
4001
13
54
2.44
2.21
3.4
1.7
90.5
89.7
%
0.30
13
54
19
96
2.02
2.08
1.4
1.6
4.4
6.1
iu/l
—
8
28
7
20
3.53
2.06
1.7
1.8
—
—
—
0
0
7
20
3.53
2.06
1.7
1.8
—
—
—
0
0
7
20
3.53
2.06
1.1
1.0
—
—
—
0
0
7
20
3.53
2.06
1.7
1.8
—
—
—
0
0
10
38
2.66
2.02
1.5
1.5
—
—
—
0
0
5
11
4.58
1.94
2.0
1.4
—
—
—
0
0
8
27
2.99
1.94
1.6
1.7
—
—
—
0
0
8
27
2.99
1.94
1.6
1.7
—
—
—
0
0
8
27
2.99
1.94
1.6
1.7
—
—
—
0
0
8
27
2.99
1.94
1.6
1.7
—
—
—
0
0
13
59
2.23
1.85
1.2
1.1
—
—
—
0
0
10
40
2.53
1.84
1.3
1.2
—
—
—
0
0
5
12
4.20
1.82
1.2
1.3
—
—
—
0
0
13
60
2.20
1.79
1.0
1.2
—
—
—
0
0
38
250
1.56
1.76
3.4
2.9
4.2
4.6
pmol/l
1.52
32
216
6
18
3.36
1.75
2.0
1.3
—
—
—
0
0
9
36
2.52
1.74
3.6
3.1
—
—
—
0
0
6
19
3.18
1.66
1.0
1.5
—
—
—
0
0
6
19
3.18
1.66
2.5
1.7
—
—
—
0
0
6
19
3.18
1.66
2.5
1.7
—
—
—
0
0
7
25
2.82
1.65
1.0
1.2
—
—
—
0
0
14
70
2.03
1.60
1.4
1.3
—
—
—
0
0
7
26
2.71
1.58
1.6
1.5
—
—
—
0
0
7
26
2.71
1.58
1.6
1.5
—
—
—
0
0
355
3292
1.23
1.49
4.9
3.9
15.0
14.8
pmol/l
0.61
332
2969
10
45
2.25
1.47
1.2
1.0
—
—
—
0
0
7
28
2.52
1.45
2.1
1.4
1.0
1.0
g/l
—
7
28
5
16
3.14
1.44
1.0
1.0
1323.8
1259.4
miu/ml
—
5
16
5
16
3.14
1.44
1.0
1.1
—
—
—
0
0
5
16
3.14
1.44
1.0
1.2
—
—
—
0
0
6
22
2.75
1.44
2.5
1.6
—
—
—
0
0
6
22
2.75
1.44
2.5
1.6
—
—
—
0
0
7
29
2.43
1.39
1.1
1.3
—
24.0
—
0
5
19
113
1.71
1.33
2.1
1.5
—
—
—
0
0
9
43
2.11
1.31
4.0
3.3
—
—
—
0
0
5
19
2.65
1.22
3.6
3.9
1051.6
84.6
nmol/l
—
5
19
57
439
1.33
1.20
5.3
3.2
—
—
—
0
0
223
2014
1.18
1.13
5.0
3.9
—
—
—
0
0
21
135
1.58
1.13
1.5
1.6
—
—
—
0
0
58
453
1.31
1.12
2.5
4.0
3.0
31.8
ug/l
1.00
46
377
10
51
1.98
1.12
1.4
1.3
—
—
—
0
0
7
32
2.20
1.08
1.6
1.4
—
—
—
0
0
16
97
1.67
1.07
1.4
1.5
—
—
—
0
0
5
23
2.18
0.98
1.0
1.1
—
—
—
0
0
7
37
1.90
0.94
2.1
1.1
1.9
1.5
nmol/l
—
7
32
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
6
28
2.16
0.91
1.2
1.2
—
—
—
0
0
117
1024
1.18
0.84
2.8
2.2
—
—
—
0
0
411
3949
1.17
0.84
5.6
4.7
1.9
2.2
mu/l
0.45
389
3590
6
33
1.83
0.79
1.3
1.2
—
—
—
0
0
9
54
1.68
0.75
1.8
1.7
—
—
—
0
0
9
54
1.68
0.75
1.8
1.7
—
—
—
0
0
9
55
1.65
0.74
1.8
1.7
—
—
—
0
0
9
55
1.65
0.74
1.8
1.7
—
—
—
0
0
9
55
1.65
0.74
1.8
1.7
—
—
—
0
0
9
55
1.65
0.74
1.2
1.1
—
—
—
0
0
9
55
1.65
0.74
1.8
1.7
—
—
—
0
0
30
386
0.76
0.71
2.6
1.8
—
—
—
0
0
14
93
1.52
0.70
3.2
2.2
114.0
131.8
g/l
—
7
69
14
93
1.52
0.70
3.0
3.8
31.7
27.1
mg/l
—
8
54
0
23
0.00
0.58
0.0
1.3
—
—
—
0
0
14
98
1.44
0.57
1.1
1.1
—
—
—
0
0
143
1310
1.12
0.56
3.2
3.2
6.7
7.4
mmol/l
1.24
124
1087
406
4176
0.89
0.56
4.9
4.5
5.7
5.9
mmol/l
4.06
378
3808
85
755
1.15
0.54
1.5
1.5
—
—
—
0
0
13
91
1.44
0.53
1.1
1.3
—
—
—
0
0
13
91
1.44
0.53
4.2
2.3
15.2
16.5
%
—
5
46
6
39
1.54
0.53
3.0
3.3
7.6
6.6
nmol/l
—
6
39
16
117
1.38
0.53
3.6
3.2
8.3
8.5
kpa
0.11
16
105
6
40
1.51
0.51
2.0
2.2
13.7
13.2
%
—
6
40
22
171
1.30
0.50
7.5
5.0
2.0
1.6
%
1.72
17
161
8
117
0.68
0.46
1.5
1.2
—
—
—
0
0
383
3935
0.91
0.45
33.7
14.4
39.3
39.8
%
0.60
266
2819
0
16
0.00
0.41
0.0
1.3
—
—
—
0
0
10
71
1.42
0.39
1.2
1.5
—
—
—
0
0
37
426
0.86
0.36
2.4
2.0
—
—
—
0
0
392
4007
0.92
0.35
6.2
5.7
39.9
39.7
mmol/mol
0.22
373
3718
40
349
1.16
0.35
2.8
2.6
72.8
67.6
ml/min/173m2
0.18
12
150
56
504
1.12
0.32
1.4
1.7
1.5
1.5
%
0.06
45
446
468
4615
1.11
0.32
25.1
10.0
31.0
25.8
u/l
6.91
461
4444
451
4446
1.09
0.28
29.7
15.4
139.4
139.7
mmol/l
1.94
441
4329
32
283
1.14
0.25
1.3
1.2
96.1
129.3
iu/ml
—
8
110
416
4096
1.07
0.24
24.3
12.5
86.6
81.3
ml/min/173m2
4.26
369
3343
16
133
1.21
0.24
9.8
3.6
3.9
3.9
mmol/l
0.08
16
122
87
927
0.93
0.24
3.6
4.3
22.1
21.5
%
0.18
44
430
135
1287
1.07
0.24
3.9
4.0
7.2
8.6
mg/mmol
0.23
85
794
5
40
1.25
0.22
1.2
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
73
685
1.08
0.20
1.6
1.4
—
—
—
0
0
451
4462
1.07
0.19
30.0
15.6
3.9
4.0
mmol/l
2.52
441
4333
17
147
1.16
0.18
2.0
1.8
—
—
—
0
0
12
142
0.84
0.17
1.2
1.5
—
—
—
0
0
7
61
1.15
0.17
2.1
1.7
—
—
—
0
0
12
101
1.19
0.16
1.8
2.2
13609.2
3223.3
u/l
—
6
33
120
1156
1.05
0.15
4.6
4.9
3.9
2.4
ug/l
0.68
109
1039
15
165
0.91
0.09
2.1
1.8
—
—
—
0
0
5
60
0.83
0.08
1.6
1.3
7.8
7.5
mmol/l
—
5
40
10
88
1.14
0.08
1.6
1.6
—
—
—
0
0
7
84
0.83
0.07
1.0
1.5
—
—
—
0
0
20
214
0.93
0.07
2.0
1.9
—
—
—
0
0
57
552
1.04
0.06
4.8
4.5
29.9
31.7
%
0.73
44
356
262
2645
0.98
0.06
3.1
2.9
—
—
—
0
0
121
1196
1.02
0.03
1.6
1.7
1.6
1.4
mmol/l
2.12
103
1008
69
682
1.01
0.01
2.7
3.0
0.7
0.8
ug/l
0.18
48
441
52
526
0.99
0.00
8.9
6.3
—
—
—
0
0
13
131
0.99
0.00
1.8
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
3.4
—
67.4
—
0
5
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
6
61
0.98
0.00
2.2
2.6
—
22.7
—
0
15
5
51
0.98
0.00
1.4
1.5
31.3
30.3
u/l
—
5
42
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
6
60
1.00
0.00
1.3
1.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: M13_DERMATOPOLY – Dermatopolymyositis
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).